ST銀河(000806.SZ)業績快報：2019年度淨虧損11.6億元
格隆匯4月14日丨ST銀河(000806.SZ)披露2019年度業績快報，實現營業總收入7.81億元，同比增長2.59%；利潤總額-11.65億元；歸屬於上市公司股東的淨虧損11.6億元，上年同期虧損7.06億元；基本每股虧損1.0546元。
2019年宏觀經濟環境更趨複雜嚴峻，企業融資難度增加，公司又因違規對外擔保、控股股東資金佔用等事項引發多起訴訟仲裁，導致公司對外融資受限，給日常生產經營造成較大的負面影響。面對內外部壓力，公司董事會和經營管理團隊積極督促控股股東加快解決資金佔用和違規擔保等問題，力爭降低違規事項給公司帶來的衝擊，同時適當調整經營策略、努力保持整體局面基本穩定。
報告期內公司變壓器業務實現減虧，電子元器件業務收入、利潤保持雙增長；生物醫藥領域，第三代EGFR抑制劑藥物已獲得臨牀試驗批件，重點研發項目有所推進，部分新藥研發項目積極引進戰略投資者以推動新藥研發進程；但因公司面對的不利因素較多，加之整體營業成本下降幅度有限，財務成本較高，以及控股股東資金佔用和違規對外擔保等事項需要計提鉅額損失，導致2019年公司業績出現大幅虧損。
報告期內，公司利潤總額、歸屬於上市公司股東的淨利潤、基本每股收益、加權平均淨資產收益率、歸屬於上市公司股東的所有者權益、歸屬於上市公司股東的每股淨資產指標較上年同期相比變動幅度超過30%，造成業績變動主要原因系：(1)公司目前存在控股股東(銀河天成集團有限公司)資金佔用的情形，考慮到控股股東目前的情況，公司對控股股東的應收款項進行大額計提減值損失；(2)公司目前存在較多訴訟仲裁的案件，並且部分涉訴案件已判決公司需承擔責任，出於會計謹慎性原則，公司對前述事項計提了預計負債並確認大額的營業外支出；(3)公司下屬變壓器企業的主要客户固定資產投資規模持續下降，導致變壓器產品總銷售收入處於歷史低位水平，而營業成本下降幅度有限，致使變壓器業務處於持續虧損中；(4)CD19CAR-T藥物、第三代EGFR抑制劑等生物醫藥項目仍處於研發階段，需要持續投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
